Clinical Trials Browser

Neoplasm, Residual × Imatinib Mesylate × Myeloid × Clear all

NCT01751425 2025-06-03

Ruxolitinib in Treating Participants With Chronic Myeloid Leukemia With Minimal Residual Disease While on Therapy With Tyrosine Kinase Inhibitors

Phase 1 Terminated

MyeloidOther hematologic neoplasm

Leukemia, Myelogenous, Chronic, BCR-ABL Positive, Neoplasm, Residual

NCT00267085 2012-08-07

Synthetic Vaccine in Patients With Chronic Myeloid Leukemia and Minimal Residual Disease

Phase 2 Completed

11 enrolled 6 charts

MyeloidOther hematologic neoplasm

Leukemia, Myelogenous, Chronic, BCR-ABL Positive, Neoplasm, Residual